ONCAlert | 2018 SGO Annual Meeting on Women’s Cancer

Cerdulatinib in Relapsed/Refractory B-Cell Malignancies

Ian W. Flinn, MD, PhD
Published Online: 2:28 PM, Wed June 3, 2015


Ian W. Flinn, MD, PhD, director, Blood Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses a phase I story which examined cerdulatinib in patients with relapsed/refractory B-cell malignancies.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.